Stocktoria
Guardant Health, Inc. GH
Guardant Health, Inc. (GH) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $982.0M at a -42.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.78 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Piper Sandler | Overweight (main) |
| 2026-08-04 | Stephens & Co. | Overweight (main) |
| 2026-08-04 | Morgan Stanley | Overweight (main) |
| 2026-08-03 | Stifel | Buy (main) |
| 2026-07-31 | RBC Capital | Outperform (main) |
| 2026-07-31 | Mizuho | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.578 |
| Retained earnings / assets | -1.487 |
| EBIT / assets | -0.217 |
| Equity / liabilities | -0.047 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
FAQ
Is GH financially healthy?
Guardant Health, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does GH pay a dividend?
No, Guardant Health, Inc. does not currently pay a dividend.
How profitable is GH?
In FY2025, Guardant Health, Inc. had a net margin of -42.4%.
What is the analyst price target for GH?
The average Wall-Street price target for Guardant Health, Inc. is $194.29, about 17.7% above the recent price, from 24 analysts (consensus: strong buy).
Is GH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Guardant Health, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.